I spent yesterday afternoon at the Forum for Medical Innovation in downtown Chicago, hosted by the Council for American Medical Innovation and moderated by former U.S. House of Representatives majority leader Dick Gephardt. The event also featured AstraZeneca CEO David Brennan as a guest speaker. [img_assist|nid=1172|title=David Brennan|desc=|link=none|align=right|width=128|height=86]
Four universities--Hawaii, MIT, Purdue, and Rutgers--are collaborating on an effort, with support from the National Science Foundation, to apply modern analytical methods to traditional medicines in order to learn more about their properties. The researchers will use informatics and bioinformatics to establish a more cohesive database on traditional medicines.
Researchers at the Salk Institute in La Jolla have discovered a drug (for more, read on) that appears to provide the same benefits as exercise: improved endurance and metabolic function-----in mice. What's next?
U.K physics professor Jim Al-Khalili recently visited the Royan Institute in Tehran to witness their work in stem cell research, and described the differences in approach in an interesting commentary in the Guardian.
Fierce Vaccines just spotlighted an article from this week's Scientific American, on a clinical trial of a vacccine for non Hodgkins lymphoma, which was derived by tobacco plants. Researchers produced tumor-fighting antigen within the plants by first extracting the gene coding for the antigen from white blood cells in patients'...
Clinical trials may have uncovered a possible link between inhaled insulin and lung cancer. In testing its blockbuster manque Exubera, Pfizer said six of the 4,740 Exubera-treated patients versus one of the 4,292 patients not treated with Exubera developed lung cancer.
Question of the day: Why do some people react to devastating news by turning inward and shutting out the world, while others "take arm against a sea of troubles, and by opposing, end them. " For anyone suffering from seasonal affective disorder (SAD) or struggling through the dog days of...
Experimental drugs and therapies are flourishing in China, and patients who feel they have little to lose are flocking there to try them, according to an article in the Asia Times, which references a study published in Nature Biotechnology. Click here to read.